Jiangsu Hengrui Pharmaceuticals(600276.SH): Clinical trials for multiple drugs including injection SHR-9839(sc) approved

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, the company and its subsidiaries Suzhou Shengdiya Biomedical Pharmaceuticals Co., Ltd., Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Shanghai Shengdi Pharmaceuticals Co., Ltd. have received approval from the National Medical Products Administration (referred to as "NMPA") to conduct clinical trials for injection SHR-9839(sc), injection SHR-A2009, injection SHR-1826, HRS-4642 injection, Adeboli monoclonal antibody injection, injection of Riconkutuzumab monoclonal antibody, injection SHR-A2102, HRS-7058 capsules, and HRS-7058 tablets. The specific clinical trial will involve a phase IB/II study on the safety, tolerability, and efficacy of the combination of injection SHR-9839(sc) with anti-tumor drugs in solid tumor subjects.